Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

PubMed

Brain-computer interface commercialization.

PMID: 41612341 · 2026

JournalJournal of neuroengineering and rehabilitation
Year2026
PMID41612341

Abstract

Brain-computer interfaces (BCIs) have emerged as powerful tools to restore neurological function lost due to injury or degeneration. Despite scientific advancements, successful commercialization remains challenging. This article analyzes two rehabilitative BCIs—the Argus II retinal prosthesis by Second Sight and the ARC-IM spinal cord stimulation system by Onward Medical—as case studies to highlight critical factors influencing their commercialization outcomes. The Argus II, initially heralded a

Official Source

View on PubMed →

Data sourced from PubMed / NCBI. For the full text and most current information, always refer to the official record.